Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares Outstanding
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Debt Repayments (2016 - 2019)

Historic Long-Term Debt Repayments for Enanta Pharmaceuticals (ENTA) over the last 5 years, with Q3 2019 value amounting to $22000.0.

  • Enanta Pharmaceuticals' Long-Term Debt Repayments rose 1000.0% to $22000.0 in Q3 2019 from the same period last year, while for Sep 2019 it was $86000.0, marking a year-over-year increase of 886.08%. This contributed to the annual value of $86000.0 for FY2019, which is 886.08% up from last year.
  • According to the latest figures from Q3 2019, Enanta Pharmaceuticals' Long-Term Debt Repayments is $22000.0, which was up 1000.0% from $22000.0 recorded in Q2 2019.
  • Enanta Pharmaceuticals' Long-Term Debt Repayments' 5-year high stood at $22000.0 during Q2 2019, with a 5-year trough of $16000.0 in Q4 2015.
  • For the 5-year period, Enanta Pharmaceuticals' Long-Term Debt Repayments averaged around $19125.0, with its median value being $19000.0 (2017).
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Long-Term Debt Repayments skyrocketed by 1250.0% in 2016, and later skyrocketed by 500.0% in 2019.
  • Enanta Pharmaceuticals' Long-Term Debt Repayments (Quarter) stood at $16000.0 in 2015, then rose by 12.5% to $18000.0 in 2016, then increased by 5.56% to $19000.0 in 2017, then rose by 10.53% to $21000.0 in 2018, then increased by 4.76% to $22000.0 in 2019.
  • Its last three reported values are $22000.0 in Q3 2019, $22000.0 for Q2 2019, and $21000.0 during Q1 2019.